tive CD during flare up. We have also reviewed the Englishlanguage literature on this topic.
INTRODUCTION
Patients with IBD have a higher risk of venous thrombosis compared with the general population. 1 The most common sites of venous thrombosis in IBD patients are the deep veins of the legs, pulmonary system, and portal and mesenteric veins. 2 However, cerebral venous thrombosis is rarely associated with IBD, and is more likely to occur as a complication of UC than of CD. 3 Cerebral venous thrombosis in patients with CD has been reported only rarely. 4 We could not perform colonoscopy or three-dimensional CT of the small bowel for workup of what appeared to be aggravated CD, because the patient was unable to drink fluids. Upper endoscopy revealed multiple erosions in the esophagus and stomach, and microscopic examination of biopsy specimens found suspicious granuloma, suggesting upper gastrointestinal involvement of CD. In a limited colonoscopic examination performed after administration of an enema, longitudinal ulcers and a cobble stone appearance with skipped patterns were observed from the terminal ileum to the proximal transverse colon (Fig. 1) . These findings had worsened since the patient' s previous colonoscopy, performed 1 year earlier. We initiated treatment with a biologic agent because her condition was declining despite administration of immune-modulating agents, and because of prognostic factors associated with poor outcomes, including her young onset of disease and involvement of the upper gastrointestinal tract. Infliximab (Remsima ® ; Celltrion, Incheon, Korea) 5 mg/kg was selected because she suffered from mental retardation and would find it difficult to selfinject medication. After treatment began, the inflammatory activity was rapidly controlled, as indicated by a decreased After consultation with neurologists, a cerebrospinal fluid analysis was performed to rule out the possibility of encephalo meningitis. Although testing revealed an elevated intracranial pressure of 220 mmH 2 O, no white blood cells or red blood cells were detected. Additionally, her protein level was 15.0 mg/dL and her glucose level was 74 mg/dL, further minimizing the likelihood of encephalomeningitis. Therefore, a CT of the brain was performed to rule out other causes of headache and to find the cause of the elevated intracranial pressure. This revealed hyper-attenuations at the anterior and medial superior sagittal sinus, right transverse sinus, and cortical veins, and thus suggested a diagnosis of cerebral venous thrombosis (Fig. 2) . The patient then underwent MRI of the brain with venography, resulting in detection of venous thrombosis in the cortical veins, superior sagittal sinus, right transverse sinus, and right internal jugular vein (Fig. 3 ). Blood tests for homocysteine, factor V, VIII, IX, XI, and vWF antigen were also performed to rule out thrombophilic conditions, and the results were normal. However, her levels of antithrombin III (126%), protein C activity (159%), and protein S activity (131%) were all high. Her D-dimer level (1.4 mg/mL) was also slightly elevated, as may occur during exacerbation of CD.
The patient was diagnosed with cerebral venous thrombosis as a complication of CD flare-up, without underlying thrombophilic conditions. She was treated with intravenous heparin (Heparin ® 25,000 IU/5mL; JW pharmaceutical, Seoul, Republic of Korea). A follow-up CT scan performed after 7 days of anticoagulation showed resolution of the dense attenuation within the superior sagittal sinus and right transverse sinus (Fig. 4) . Her headache and vomiting improved after 9 days of treatment, and completely disappeared after 14 days. An MRI with venography was conducted after 2 weeks of anticoagulation and showed resolution of the venous thrombosis with recanalization of the cortical veins, superior B A (Fig. 5) .
The patient was discharged on a regimen of rivaroxaban (Xarelto ® ; Bayer HealthCare AG, Leverkusen, Germany) 10 mg daily, with treatment continued for 6 months. She remained stable, without neurological damage.
DISCUSSION
IBD can be complicated by a variety of extra-intestinal conditions, including venous thrombosis due to hypercoagulability. In Korea, a few cases of thrombotic complications in patients with CD have been reported (Table 1) . [5] [6] [7] [8] [9] In cases of venous thrombosis, cerebral vascular involvement is very rarely observed. 4, 5 Cerebral venous thrombosis can be accompanied by neurologic abnormalities caused by rapidly elevating intracranial pressure, and can result in serious adverse events. Therefore, early differential diagnosis of this rare complication is important for CD patients complaining of headache and vomiting. In a study that retrospectively analyzed data from 65 case reports of IBD patients with cerebral venous thrombosis, the average patient age was 29, and women experienced complications more frequently than men (37 vs. 28). 3 The incidence of UC was almost double compared with CD (42 vs. 21), and active disease was reported in 78.4% of the cases. The predominant neurological symptoms were headache (80%), seizure (35%), vomiting (29%), hemiplegia or tetraplegia (29%), altered consciousness (21%), vision deficits (12%), and papilledema (7%). The most common site of cerebral venous thrombosis was the superior sagittal sinus (50.7%), and thrombosis in multiple sites occurred in about 50% of cases, like the one we have reported here. The main risk factors for hypercoagulability were anemia (49%) and thrombocytosis (26%); however, there were many cases (23%) accompanied by coagulation In patients with IBD complicated by cerebral venous thrombosis, favorable outcomes are possible with early diagnosis and appropriate treatment. However, when patients are not treated, the mortality rate can be as high as 50%. 3 Therefore, physicians should be especially careful to consider the possibility of cerebral venous thrombosis in patients with IBD, especially when there is active disease, as in our case. Treatment of cerebral venous thrombosis must continue for at least 3 months, but if there are risk factors for thrombosis, coagulation abnormalities, or thrombogenic mutation, then long term treatment of more than 6 months should be maintained. 15 Since the underlying IBD can be a cause of thrombosis, treatment of the inflammation itself is essential. 11 In our case, the patient' s inflammatory activity of CD was rapidly controlled with a biologic agent, and anticoagulation with intravenous heparin reversed her thrombophilic conditions. Although this is the second case reported in Korea of CD complicated by cerebral venous thrombosis, this is the first case in active CD without underlying thrombophilic conditions. Once again, a high level of concern for cerebral venous thrombosis is important when treating active IBD patients, because anticoagulation may prevent fatal complications.
